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Abstract
Background: ICU patients must be kept conscious, calm, and cooperative even during the critical phases of illness.
Enteral administration of sedative drugs might avoid over sedation, and would be as adequate as intravenous
administration in patients who are awake, with fewer side effects and lower costs. This study compares two
sedation strategies, for early achievement and maintenance of the target light sedation.
Methods: This was a multicenter, single-blind, randomized and controlled trial carried out in 12 Italian ICUs,
involving patients with expected mechanical ventilation duration > 72 h at ICU admission and predicted mortality > 12%
(Simplified Acute Physiology Score II > 32 points) during the first 24 h on ICU. Patients were randomly assigned
to receive intravenous (midazolam, propofol) or enteral (hydroxyzine, lorazepam, and melatonin) sedation. The
primary outcome was percentage of work shifts with the patient having an observed Richmond Agitation-Sedation
Scale (RASS) = target RASS ±1. Secondary outcomes were feasibility, delirium-free and coma-free days, costs of drugs,
length of ICU and hospital stay, and ICU, hospital, and one-year mortality.
Results: There were 348 patients enrolled. There were no differences in the primary outcome: enteral 89.8% (74.1–100),
intravenous 94.4% (78–100), p = 0.20. Enteral-treated patients had more protocol violations: n = 81 (46.6%) vs 7 (4.2%),
p < 0.01; more self-extubations: n = 14 (8.1%) vs 4 (2.4%), p = 0.03; a lighter sedative target (RASS = 0): 93% (71–100) vs
83% (61–100), p < 0.01; and lower total drug costs: 2.39 (0.75–9.78) vs 4.15 (1.20–20.19) €/day with mechanical
ventilation (p = 0.01).
Conclusions: Although enteral sedation of critically ill patients is cheaper and permits a lighter sedation target, it
is not superior to intravenous sedation for reaching the RASS target.
Trial registration: ClinicalTrials.gov, NCT01360346. Registered on 25 March 2011.
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Introduction
The management of pain, agitation, and delirium is a
key point in the care of critically ill patients [1]. Once
triggering conditions have been dealt with, pharmaco-
logical treatment becomes necessary. After adequate
analgesia, sedative drugs, usually given by continuous
intravenous (IV) infusion, ensure comfort and allow
life-saving procedures, constituting an invaluable tool
during the ICU stay. However, they have several side ef-
fects [2, 3]. International guidelines [4, 5] suggest using
the lowest effective doses for early achievement [6, 7]
and constant maintenance of a light level of sedation
even in the most severe conditions [8, 9]. Several strat-
egies have been proposed to avoid deeper-than-needed
[10] levels of sedation, aiming for the goal of keeping
ICU patients “calm, conscious, and cooperative” [11–13].
However, even if unjustified [8], a large proportion of
ICU staff still tend to consider this unfeasible [14] be-
cause of the risk of self-removal of invasive devices [15],
the fear of greater stress/discomfort among patients, and
the increased workload for operators. Despite the wide-
spread use of validated scoring systems for sedation, like
the Richmond Agitation and Sedation Scale (RASS) [16],
a very large proportion of ICU patients are kept at a sed-
ation level deeper than desired [10, 17], quite likely caus-
ing avoidable side effects.
With continuous intravenous (IV) infusion one can
predict the duration of the drug effect using pharma-
cokinetic calculations. This approach, safe for patients
with a short ICU stay, could be useless or dangerous
in patients needing mechanical ventilation (MV) for
more than 3 days. In these cases, it may cause over-
administration [18] even with adequate sedation targets.
Moreover, the daily awakening trials [15] could induce
non-physiological neurological fluctuations, preventing
the formation of factual memories, and becoming a pre-
cipitant cause of delirium [19], leading to post-ICU cogni-
tive dysfunction [20].
Analgesic [21] and sedative [22] drugs are rarely ad-
ministered enterally (EN) because of their slower onset
of effect and unpredictable pharmacokinetics, even
when intestinal absorption is adequate from ICU ad-
mission [23]. Our “EN sedation” protocol [24] uses hy-
droxyzine (a first-generation antihistaminic drug, with
antiemetic and gastric antisecretory properties) and al-
lows the addition of low doses of lorazepam (a medium-
half-life benzodiazepine) if necessary. Melatonin is con-
tinuously used [25] as a physiological sleep-inducer, with
antioxidant, anti-inflammatory, analgesic, and immune-
modulating properties [26, 27].
The longer onset and offset time of EN administration
make this approach difficult. However, at the same time,
this route ensures a more stable level of consciousness with
less neurological fluctuation and fewer cardiorespiratory
side effects. EN drugs cost much less than IV ones [22],
are less likely to lead to deep sedation, and are similarly
effective as judged by nurses, if an awake target is de-
sired [12].
The hypothesis of the present study is that an unusual
EN sedative drugs administration protocol could reach
and maintain light and effective sedation, compared to
the more common IV continuous infusion. The main
outcome was achievement of the target sedation level in
ICU patients needing MV for more than 72 h.
Methods
Study design
The methods have been described in detail elsewhere
[24]. Briefly, the “Enteral versus intravenous sedation
trial (SedaEN)” is a randomized, controlled, multicenter,
single-blind trial (ClinicalTrials.gov, NCT01360346), to
compare two protocols for sedation management, both
used after adequate analgesia. In the control group, pro-
pofol or midazolam were given by IV infusion. In the
intervention group, melatonin, hydroxyzine, and possibly
lorazepam were administered enterally, while IV drugs
were allowed during the first 48 h on ICU [25].
Setting
The 12 Italian participating ICUs were selected on the
basis of their availability to use two very different pro-
tocols simultaneously; in order to obtain the best
generalizability, they were heterogeneous in terms of
patient case-mix, central/rural area, previous know-
ledge about EN sedation, and belonging to academic
hospitals. To help in caring for complex cases, three
flowcharts were proposed, for pain, agitation, and delir-
ium management [24]. Weaning from MV was not set
in the protocol, but was managed according to local
guidelines in both groups.
Participants
Inclusion criteria were age ≥ 18 years, MV duration > 72
h as estimated by the physician in charge at ICU admis-
sion, and Simplified Acute Physiology Score II (SAPS II)
[28] > 32 points during the first 24 h on ICU, corre-
sponding to expected mortality > 12%. Exclusion criteria
are set out in Fig. 1. A study sample of 300 patients was
calculated as required in order to detect a clinically rele-
vant difference in the main outcome [24].
Randomization and masking
Patients were randomized through a centralized website
[24]. After written informed consent had been obtained
from patients or relatives according to the indications of
the 12 local ethics committees that approved the study,
the group allocation was established with a minimization
algorithm balanced within centers. Once a patient was
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assigned, no change of protocol arm was allowed. Staff
members were aware of the group assignment, as it was
not possible to blind staff to the sedative drug adminis-
tration route.
Procedures
According to a patient-centered approach [1, 4, 5], in
both groups the attending physicians were invited to
state the target sedation level for each work shift, aiming
as soon as possible for a conscious, calm, and coopera-
tive target, and to titrate doses of sedatives early with
the rule of “timing, adequacy, de-escalation”. Physicians
on duty discussed prescriptions at least twice a day dur-
ing handovers. Nurses assessed the depth of sedation, in-
dicating the prevalent RASS level in their work shift,
and stated whether the prescriptions were adequate for
the severity of the illness, the invasive procedures, and pa-
tients’ surveillance and security. Even though protocol vio-
lations were strongly discouraged, they were always
allowed and recorded. IV boluses of analgesics (fentanyl
or morphine) and/or IV sedatives (propofol or midazolam)
were not considered violations in the EN arm when used
for extemporary invasive/painful/surgical procedures.
Outcomes
The main outcome was the percentage of work shifts in
which the desired sedation level was reached or nearly
reached (observed RASS = target RASS ±1). The second-
ary outcomes were feasibility of the sedation protocol
(percentage of shifts with assigned protocol violations);
delirium-free and coma-free days, assessed by the Con-
fusion Assessment Method for ICU (CAM-ICU) [29]
Fig. 1 The Consolidated Standards of Reporting Trials (CONSORT) diagram for screening and randomization in the “Enteral versus intravenous
sedation” (SedaEN) trial. The 339 patients were analyzed using an intention-to-treat approach, without considering treatment interruptions. ICU,
intensive care unit; MV, mechanical ventilation; SAPS II, Simplified Acute Physiology Score II; CNS, central nervous system; DNR, do not resuscitate
orders; IV, intravenous; EN, enteral
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and RASS (coma was defined by RASS levels of − 4
and − 5); ventilation-free days; nursing assessment of
the adequacy of sedation (anxiety, cooperation, toler-
ance of the environment); length of ICU stay; ICU,
hospital, and one-year mortality; hospital costs for
neuroactive drugs [30]. Adverse events such as self-
extubation and removal of other invasive tools, un-
scheduled diagnostic neurological tests, anxiety, hours
of sleep and agitation, and use of anti-psychotics,
pharmacological antagonists, or physical restraints were
recorded.
Statistical analysis
An intention-to-treat statistical approach was planned,
because the violation rate was unpredictable a priori.
Baseline patient characteristics and single-observation
outcomes were analyzed by two-tailed tests: the Wil-
coxon rank-sum test for analysis of continuous data and
Fisher’s exact test for analysis of categorical data. We
performed repeated measures analysis for data recorded
during the whole ICU stay; comparisons were made by
multilevel mixed-effects Poisson regression. This statis-
tical approach was selected to simultaneously analyze
the net effects of group assignment, the effect of time
spent in ICU, and the cumulative effect of the sedatives,
as calculated by multiplying the group (EN = 1, IV = 0)
and the ICU day from group assignment, to highlight
the adjunctive effects of the daily EN doses of sedatives.
Mortality was analyzed by log-rank test and presented
as Kaplan–Meier curves, without adjustment for base-
line covariates. There were no missing data on the main
outcome, as the centralized website needed these data to
be completed before allowing the validation of each pa-
tient’s recordings. The Stata 12 statistical package (Stata
Corporation, College Station TX, USA) was used for all
statistical analyses.
After the first 140 patients were enrolled, an interim
analysis was planned. The results were discussed in a
steering committee meeting (28 May 2012). In the
power calculation, a study sample of 141 patients per
group (power 80%, alpha 0.05) was calculated as suffi-
cient to observe a 15% difference in the prevalence of
sedation adequacy (observed RASS = target RASS ±1)
between the two study arms: such a difference was con-
sidered clinically relevant and likely to influence medical
practice. To allow for missing data, a total of 300 pa-
tients was expected to be enrolled, with at least 20
patients per ICU [24].
Results
Participants
The characteristics of the 12 participating ICUs are de-
scribed in Additional file 1: Table E1. During the study
(24 January 2012 to 31 December 2012), 2914 critically
ill patients were admitted and screened; 348 of them
were randomized (Fig. 1). The baseline characteristics of
patients at ICU admission are presented in Table 1; the
two groups were adequately balanced according both the
criteria stated a priori and in the other clinical
parameters.
Interim analysis
No serious adverse events were reported, and there was
a significant difference in the RASS target: patients in
the EN group were more frequently at a conscious level
(RASS = 0) than those randomized to the IV group.
Clear recommendations were communicated to all the
local investigators during the two planned meetings
(24–25 March and 15 September 2012), and during the
principal investigator’s visits to each participating center.





Age, median [IQR], yearsa 71 [62–77] 73 [62–78]
Mena 107 (64.8) 109 (62.6)
BMI, median [IQR] 25.9 [23.7–29.4] 26.1 [23.4–29.4]
Severe sepsis or septic shocka 48 (29.1) 64 (36.8)
SAPS II score, median [IQR]a, b 45 [38–55] 46 [38–54]
SOFA score, median [IQR] c 8 [5–10] 7 [5–10]
Type of admissiona, d
Medical 110 (66.7) 114 (65.5)
Surgical/traumatic 55 (33.3) 60 (34.5)
Admission from
Emergency room 55 (33.3) 61 (37.0)
Ward 55 (33.3) 59 (35.8)
Operating theatre 39 (23.6) 34 (20.6)
Other ICU 16 (9.7) 20 (12.1)
Reason for ICU admissione
Respiratory failure 97 (58.8) 101 (58.0)
Cardiac failure 38 (23.0) 40 (23.0)
Neurologic failure 11 (6.7) 12 (6.9)
Monitoring 6 (3.6) 9 (5.2)
Other 13 (7.9) 12 (6.9)
Acute or chronic kidney failurea 30 (18.2) 43 (24.7)
Moderate to severe COPDa 50 (30.3) 53 (30.5)
Abbreviations: EN enteral, IV intravenous, BMI body mass index, IQR
interquartile range, SAPS Simplified Acute Physiology Score, SOFA Sequential
Organ Failure Assessment, COPD chronic obstructive pulmonary disease, ICU
Intensive Care Units
aCharacteristics used by the minimization algorithm for the group assignment
bSAPS II may range from 0 to 163 points, with higher scores indicating more
severe diseases
cSOFA score may range from 0 to 24 points, with higher scores indicating
more severe diseases
dSurgical/trauma refers to admission from an operating room or postoperative
recovery area
eMain reasons for admission are mutually exclusive
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Even though they progressively decreased, these differences
remained statistically significant until the study ended
(82.9 vs 93.3%, p < 0.01).
Outcomes
The primary outcome of achieving the RASS target
(Fig. 2a) was not different in the two groups (94.4 vs
89.8%, p = 0.20) (Table 2). Since the prevalence of RASS
target = 0 was higher in the EN group, a multivariate
generalized linear model was built to control for all the
covariates: the effect of study group on the main out-
come was confirmed as not significant (Additional file 1:
Table E2).
The prevalence of adequacy as judged by nurses was
not different for the EN and IV groups (89.7% vs 92.4%,
p = 0.11), but there were significantly more protocol vio-
lations in the EN group. The reported reasons for viola-
tions are presented in Additional file 1: Table E3. No
differences were evident in coma-free, delirium-free, or
ventilator-free days. Mortality did not differ between the
groups either in the ICU (Additional file 1: Figure E1) or
in hospital, or thereafter until one year after ICU dis-
charge. There were more unplanned self-extubations in
the EN group; however, there were no significant differ-
ences in the need to replace the endotracheal tube and
none of these events were associated with death or other
serious complications.
The drug doses and costs are presented in
Additional file 1: Table E4. Daily doses of sedatives
were very low overall and were similar to those in
other studies [31]. Daily charges for planned seda-
tives were lower with the EN approach (1.64 vs
0.38 €/day, p < 0.01), but because unplanned seda-
tives were used more frequently, the sums of all
daily charges for sedatives during MV did not differ
between the groups (1.64 vs 0.74 €/day, p = 0.16).
Considering all the neuroactive drugs used together
(sedatives, analgesics, and antipsychotics), the total
a
b
Fig. 2 A Percentage of shifts in total ICU stay. Main outcome means the Richmond Agitation Sedation Scale RASS observed = RASS target ±1. RASS at
target means RASS observed = RASS target. Too sedated means RASS observed < RASS target. Too agitated means RASS observed > RASS target. B
Absolute number of RASS observations. *P <0.05. ICU, Intensive Care Unit; IV, intravenous; EN, enteral
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daily cost was significantly lower in the EN group (4.15 vs
2.39 €/day, p = 0.01).
Neurological observations were gathered during each
staff shift, and are presented in Table 3. Patients in the
EN group had higher RASS values, both for the target
and for the actual value (Fig. 2b); the prevalence of coma
was lower in this group, with no difference in the preva-
lence of delirium.
There were minor differences between groups in clin-
ical observations, and they arose only after considering
the effects of time and group assignment together (Add-
itional file 1: Table E5). The prevalence of sepsis was
similar in the two groups, with no differences in the Se-
quential Organ Failure Assessment (SOFA) scores. Inter-
estingly, even though this was not an outcome of the
study, the EN sedation group received a larger amount
of EN nutrition, both as planned calories - IV 22.6
(14.2–25) vs EN 23.6 (14.2–28.4) and as delivered calo-
ries - IV 22.3 (14.0–25.0) vs EN 22.8 (13.4–28.1) kcal/kg
of ideal body weight, p < 0.01 for both comparisons.
Discussion
This study compared two very different approaches for
the management of agitation in critically ill patients,
using different sedative drugs administered by the un-
usual EN route compared to the more common IV
route. No real differences were found in the most im-
portant clinical outcomes.
In agreement with international guidelines [1, 4, 5],
the target was a conscious patient for more than 80% of
ICU days. This target was set more frequently in the EN
group, but was achieved equally in both groups.
Among neurological indicators, studied throughout
the ICU stay, the EN sedation protocol resulted in a
similar incidence of delirium, while the RASS observed
was slightly higher (Fig. 2b), which means a lower inci-
dence of coma, but greater psychophysical agitation
too. Indeed, the few self-removals of endotracheal tubes
- about 5% among all participants - were more preva-
lent in the EN group. However, none of these caused
death or serious complications, and the need to replace






Percentage of shifts at target RASS = 0, median [IQR] 82.9 [61.3–100] 93.3 [70.8–100] < 0.01
Percentage of shifts at observed RASS = 0/− 1, median [IQR] 57.9 [33.3–77.8] 60.1 [33.3–83.7] 0.53
Main outcome
Percentage of shifts at RASS observed = target ±1, median [IQR] 94.4 [77.8–100] 89.8 [74.1–100] 0.20
Secondary outcomes
Percentage of adequate sedation, as judged by nurses, median [IQR] 92.4 [80.9–100] 89.7 [76.2–100] 0.11
Percentage of shifts with protocol violation, median [IQR] 0 [0–0] 0 [0–24.1] < 0.01
Patients with protocol violation, n (%) 7 (4.2) 81 (46.6) < 0.01
Coma-free days 27 [19–28] 27 [18–28] 0.80
Delirium-free days 27 [19–28] 27 [15–28] 0.40
Coma and delirium-free days 25 [11–28] 25 [10–28] 0.61
Ventilator-free days 21 [3–27] 22 [2–26] 0.89
Length of ICU stay 10 [6–18] 10 [6–18] 0.75
Mortality
In ICU, n (%) 41 (24.8) 45 (25.9) 0.90
In hospital, n (%) 54 (32.7) 62 (35.6) 0.65
One year, n (%) 68 (43.9) 71 (43.0) 0.82
Daily cost for planned sedatives, €/ventday 1.64 [0.15–4.78] 0.38 [0.22–0.60] < 0.01
Daily cost for unplanned sedatives, €/ventday 0 [0–0] 0.16 [0–2.15] < 0.01
Daily cost for all neuroactive drugs, €/ventday 4.15 [1.20–20.19] 2.39 [0.75–9.78] 0.01
Self-removal of ET tube, n (%) 4 (2.4) 14 (8.1) 0.03
Need to replace ET tube, n (%) 3 (1.8) 10 (5.7) 0.09
Self-removal of other invasive tools, n (%) 21 (12.7) 29 (16.7) 0.36
Unscheduled neurological tests, n (%) 30 (18.2) 33 (19.0) 0.89
Abbreviations: IV intravenous, EN enteral, RASS Richmond Agitation Sedation Scale, ICU Intensive Care Unit, ventday day with mechanical ventilation,
ET endotracheal
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the tube was not different between groups, as reported
elsewhere [15].
The feasibility of EN sedation was lower, as this strategy
was associated with a higher incidence of protocol viola-
tions. It is impossible to say whether these violations were
due to higher sedation targets being set by physicians, in-
adequate drug dosage, or timing of administration. This
last point was frequently reported as a problem in centers
not used to managing EN sedatives. The raw number of
violations has to be considered together with the very dif-
ferent amounts of unplanned drug administered, at times
reaching up to one third of the planned amounts for pro-
pofol. The absolute difference in the proportions of work
shifts with violation was 19.2% in the EN group and 10.7%
in the IV group. The EN group had a smaller number of
violations in a larger number of patients (46.6% vs 4.2%),
meaning that the reasons for violating the protocol were
not the same throughout the ICU stay. Perhaps for this
reason, nurses judged the EN sedation as being as ad-
equate as IV sedation (89.7 vs 92.4%). From these figures,
the separation between EN and IV sedation may seem an
academic question and in many cases a combination of
both might provide a more rational approach.
In managing psychophysical agitation, one must con-
sider the pros and cons of physical and pharmacological
means of contention (restraints and drugs) [32]. The cul-
tural evolution [33] in the management of conscious
critically ill patients involves greater consideration of
their surveillance. An updated approach should integrate
the MV mode and weaning process, body posture and
physiotherapy, nutrition, and communication strategies -
also involving relatives at the bedside in ICUs that are
open to family visitors.
Interestingly, in the EN group there was a significant
tendency to a lower impact on organ function: MV was
more assisted than controlled, urinary output was higher,
infection signs were weaker, gastrointestinal motility
worked better (Additional file 1: Table E5).
The present study brings to light the need for clinical/
cultural change [33] on two key points regarding the
management of sedation therapy. First, despite great ef-
forts to recommend aiming for the same RASS target in
both arms, this decision was unexpectedly influenced by
the group assignment (target RASS = 0 in 93.3% of the
EN vs 82.9% of the IV group). Since this study is part of
an educational research project, specific online medical
education courses [34] were offered. All staff members
were invited to increase their knowledge and to use vali-
dated tools to evaluate pain, sedation, and delirium.
Moreover, since they had to simultaneously manage two
different protocols, a phone counseling service from the
coordinating center was always available. Despite this,
different sedation targets remained, probably because of
different knowledge and expertise in the use of the two
protocols, requiring the titration of drugs with different
pharmacokinetics. The “fear” of a lighter sedation target
probably increased when IV drugs with a short half-life
were used: since their effect could run out in a few mi-
nutes, the patient might become suddenly agitated. On
the other side, a “fear of oversedation” due to accumula-
tion of oral drugs could have played a role in targeting
lighter sedation in the EN group.






Maximum number of theoretical observations 5529 6663 group time group*time
Pain (VNR≥ 3 or BPS≥ 6), n (%) 663 (12.0) 734 (11.0) 0.73 0.29 0.12
Anxiety (VNR > 0), n (%) 511 (33.7) 574 (32.4) 0.99 0.17 0.14
Physical restraint use > 1 h, n (%) 694 (18.0) 785 (16.2) 0.62 < 0.01 0.42
Sleep time > 2 h observed by nurses, n (%) 571 (86.1) 649 (86.3) 0.81 < 0.01 0.07
Agitation hours > 1, n (%) 311 (20.3) 304 (17.6) 0.81 0.46 0.51
Coma- and delirium-free shift, n (%) 3004 (64.5) 3552 (64.8) 0.20 < 0.01 < 0.01
Delirium (CAM-ICU ⊕), n (%) 644 (13.8) 998 (18.2) 0.72 0.02 0.98
Coma (RASS = − 4 or − 5), n (%) 1009 (21.7) 933 (17.0) 0.11 < 0.01 < 0.01
Sedation adequacy, n (%)
Insufficient 483 (8.9) 682 (10.4) 0.65 0.28 0.62
Adequate 4664 (85.4) 5324 (81.1)
Excessive 313 (5.7) 555 (8.5)
Variables are presented as absolute number (percentage of gathered observations). Comparisons made by multilevel mixed-effects Poisson regressions to
simultaneously analyze the net effect of group assignment; the effect of time spent in ICU; the cumulative sedative effect, calculated by multiplying the group
(enteral = 1, intravenous = 0) and the number of ICU staff shifts from group assignment, to highlight the adjunctive effects of the repeated sedative administration
Abbreviations: IV intravenous, EN enteral, VNR verbal numeric rating, BPS Behavioral Pain Scale, RASS Richmond Agitation Sedation Scale, CAM-ICU Confusion
Assessment Method for Intensive Care Unit
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Second, the habitual use of IV sedation led physicians to
plan and administer smaller amounts of enteral nutrition,
probably because they know its side effects on gastrointes-
tinal motility. In this context, the challenge to accept less
powerful drugs (like hydroxyzine) and to keep patients
more awake might serve as a means for introducing good
clinical practices.
The adequacy of nutrition and drugs administered
through nasogastric/nasojejunal tubes strongly depends
on the ICU staff teamwork and problem-solving atti-
tudes. In order to obtain the best results with such EN
drugs with slow onset and offset, we recommended
starting with the highest doses in the first 24 h on ICU,
to withdraw the IV drugs early. Thereafter, the drugs
could be accurately titrated by using validated tools to
measure the results, together with a constant effort to
decrease/suspend the drugs as early as possible.
Hospital charges for the drugs are altogether very low
in relation to other ICU costs. The charges for planned
sedatives were lower in the EN group and were higher
for unplanned drugs. Considering the costs for neuroac-
tive drugs altogether, there was a significant difference
(IV 4.15 vs EN 2.39 €/MV day), meaning both that
charges for antipsychotics were not increased, and
charges for analgesics were slightly lower, probably be-
cause of melatonin’s pain-relieving effect [35]. These
charges are much lower than those reported in the lit-
erature; hospital costs could be significantly higher with
respect to new drugs and approaches, like dexmedetomi-
dine or sevoflurane [25].
Study limitations and strengths
The unexpected difference in RASS targets was a signifi-
cant limitation of this study, which might have favored
the IV sedation protocol: as the patients were wanted to
be more sedated, reaching such a target was easier.
There are also several other limitations, like the
single-blind design of the study, the data recording by
clinical staff, the lack of anamnestic data on alcohol or
substance abuse, the non-protocolized weaning from
MV, the lack of a long-term cognitive outcome evalu-
ation, and the sedation assessment over a whole nursing
shift (prevalent RASS), which is very subjective. More-
over, some clinical practices were being introduced for
the first time (EN protocol, conscious target, use of vali-
dated tools for neurological monitoring) in a substantial
proportion of centers when the study was started. Data
were gathered some years ago, and different skills and
habits among intensivists in the use of sedatives could
have played some role, particularly in the use of benzo-
diazepines, which is discouraged nowadays. Last, half
the patients in the EN group had protocol violations,
meaning the groups were not adequately separated.
The strengths of the present study are its design coher-
ent with guidelines, always suggesting an early conscious
sedation target [1]. Rather than making it different in the
two groups [31, 36], two separate strategies were com-
pared in the achievement of the same shared goal: a calm,
conscious, and cooperative critically ill patient. Moreover,
the lack of homogeneity among participant centers could
render the results generalizable. Even with the large num-
ber of violations, the two strategies seem to be compar-
able: non-skilled centers can immediately use the EN
strategy too.
Conclusions
The EN protocol for the management of sedation in
high-risk critically ill patients was not associated with
any improvement in the rate of achievement of the de-
sired level of sedation. Some hypothesis-generating ad-
vantages, like the light sedation target or the lower costs,
might reflect a cultural change regarding the EN route.
The use of this route for “gentle patient sedation” ap-
peared possible and safe: when aiming at the target of a
conscious critically ill patient, this unusual approach -
based on drugs with weaker and longer effect - does ap-
pear to offer some benefits.
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Multivariate generalized linear model of main outcome. Table E3 Reasons
for protocol violation. Table E4 Neuroactive drug doses and hospital
charges. Table E5 Daily clinical measurements. Figure E1 Kaplan–Meier plot
for ICU survival estimates. (DOC 3129 kb)
Abbreviations
BMI: Body mass index; BPS: Behavioral Pain Scale; CAM-ICU: Confusion
Assessment Method for ICU; COPD: Chronic obstructive pulmonary disease;
EN: Enteral; ET: Endotracheal; ICU: Intensive care unit; IQR: Interquartile range;
IV: Intravenous; MV: Mechanical ventilation; RASS: Richmond Agitation
Sedation Scale; SAPS: Simplified Acute Physiology Score; SedaEN: Enteral
versus intravenous sedation trial; SOFA: Sequential Organ Failure Assessment;
VNR: Verbal numeric rating
Acknowledgements
The authors thank all the staff members of the participating ICUs for their
essential cooperation. The corresponding author would like to dedicate the
present study to the memory of Marco Rambaldi (1954-2014), friend and
master, Steering Committee member and head of the Modena center, who
was an insightful example of researcher, physician, and man. This publication
endorses the “Humanization to Enhance Recovery On Intensive Care bundle”
(www.heroicbundle.org). We are grateful to J D Baggott for language editing.
Complete list of SedaEN investigators
Steering Committee members
Gaetano Iapichino (Study Chair), Alberto Morabito (Chair of Statistics,
Dipartimento di Scienze cliniche e di comunità, Università degli Studi di
Milano), Martin Langer (Dipartimento di Oncologia e Onco-Ematologia,
Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale
dei Tumori, Milano), Roberto Malacrida (Fondazione Sasso Corbaro, Bellinzona,
Switzerland), Franco Valenza (Dipartimento di Fisiopatologia medico-chirurgica
e dei trapianti, Università degli Studi di Milano), Marco Rambaldi (Nuovo
Ospedale Civile Sant'Agostino Estense, Modena), Giovanni Mistraletti
(Principal Investigator).
Investigators from the 12 participating centers
Mistraletti et al. Critical Care            (2019) 23:3 Page 8 of 10
ASST Santi Paolo e Carlo, Ospedale San Paolo – Polo Universitario, Milano:
Davide Chiumello, Giovanni Mistraletti, Michele Umbrello, Paolo Formenti,
Paolo Spanu, Stefania Anania, Elisa Andrighi, Alessandra Di Carlo, Federica
Martinetti, Serena Barello, Andrea Noto, Gianfranco Capello, Bruno Sabatelli,
Giovanni Brenna, Morena Astori, and Pietro Placido.
IRCCS Ospedale Maggiore Policlinico, Milano: Luciano Gattinoni, Alessandro
Protti, Paolo Cadringher, Riccarda Russo, Francesca Pagan, Virna Berto, and
Paola Roselli.
ASST Monza, Ospedale di Desio (MI): Giulio Ronzoni, Eduardo Beck, Silvia
Francesconi, and Maurizio Gaiotto.
ASST Ovest Milanese, Ospedale Nuovo di Legnano (MI): Danilo Radrizzani,
Luca Ferla, Federico Valdambrini, Riccardo Giudici, and Laura Merlini.
ASST Monza, Ospedale San Gerardo, Monza (MB): Antonio Pesenti, Giacomo
Bellani, Alessia La Bruna, Emanuele Rezoagli, and Alberto Lucchini.
IRCCS San Matteo, Pavia: AR1 Antonio Braschi, Alessandra Palo, Thekla Niebel,
Marina Selvini, Sergio Cortesi, and Attilio Quaini; AR2 Giorgio Iotti, Francesca
Riccardi, Enrico Contri, and Antonella Sacchi.
AO San Giovanni Bosco, Torino: Sergio Livigni, Giuseppe Naretto, Enrica
Ferretti, Alessandro Deprado, and Virna Venturi degli Esposti.
AOU San Luigi Gonzaga, Orbassano (TO): Pietro Caironi, Giulio Radeschi,
Maurilio Festa, Lorenzo Odetto, Daniele Ferrero, Stefano Cognolato, Roberto
Penso, and Roberta Vacchelli.
AO Ospedale Cardinal Massaia, Asti: Silvano Cardellino, Edda Bosco, Anna
Maria Gado, Anna Bresciani, Ivana Pozzo, Annachiara Alessio, Vanessa
Clarindo Rodrigues, and Edna Biase.
AON SS.Antonio e Biagio e Cesare Arrigo, Alessandria: Nicoletta Vivaldi,
Martina Taverna, and Antonella Nava.
Nuovo Ospedale Civile Sant’Agostino Estense, Modena: Marco Rambaldi,
Cristina Pinna, Francesco Ponzetta, Lucilla Bavutti, Paola Martina, Beatriz
Palacios, and Giancarla Bergonzini.
Take-home message
In 348 randomized ICU patients, an unusual enteral sedation protocol
(hydroxyzine, lorazepam, and melatonin) gave no differences in clinical
outcomes but lower costs than the more common intravenous sedation
(propofol, midazolam). Mechanically ventilated patients may require different
strategies to manage pharmacological sedation best: “gentle” enteral
administration of drugs with longer half-life, accurately titrated to the lowest
effective doses, could be an option to aim for, and to maintain them at a
light level of sedation.
140-character Tweet
Enteral sedation (hydroxyzine, lorazepam, melatonin) was not superior to
intravenous (propofol, midazolam), and cost less in ICU patients.
Funding
This study received a grant for independent research provided by the
Regione Lombardia (DRL 13465 of December 22, 2010). The funder of
the study had no role in study design, data collection, data analysis,
data interpretation, or writing the report. The corresponding author,
Giovanni Mistraletti, MD, had full access to all the data in the study and
had final responsibility for the decision to submit. He takes responsibility
for the integrity of the data and the accuracy of the data analysis.
Availability of data and materials
The datasets used and analyzed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
GM is the principal investigator of the study and responsible for the
conception, protocol design, and organization of financial support. GI
applied for and received financial support from the Regione Lombardia
to start this clinical trial. MU, SS, AB, and PAF provided statistical guidance, and
were responsible for estimating the sample size and for final statistical analysis.
PC was responsible for designing and managing the specific software used for
patient allocation. PF, RR, SF, FV, GB, AP, FR, EF, MF, AMG, MT, and CP
were responsible for enrollment of patients and data gathering at each
study site. GM wrote the first manuscript draft; GI, MU, PF, DC, and PC
revised the draft for important intellectual content. All authors have read
and approved the final version and submission of the present manuscript to
Critical Care.
Ethics approval and consent to participate
All participating centers obtained local ethics committee approvals to conduct
the trial.
The coordinating center approval was issued by Comitato Etico of A.O.
San Paolo - Polo Universitario, Milano: Prot.34/Reg.delibere 2011/CE on
23 February 2011.
The other ethics committees were:
– Comitato Etico Interaziendale for the centers A.O.N. SS. Antonio e
Biagio e Cesare Arrigo, Alessandria, and A.O. Ospedale Cardinal
Massaia, Asti: Prot. 20848 on 16 September 2011
– Comitato Etico of A.O. Ospedale Civile di Desio (MI): Prot. 17235 on 28
July 2011
– Comitato Etico of A.O. Ospedale Civile di Legnano (MI): Prot. 15/12 on
18 May 2012
– ‘Comitato etico’ of N.O.C. Sant’Agostino Estense, Modena: Prot. 3083/CE
of September 13, 2011.
– Comitato Etico of A.O. San Gerardo, Monza (MB): Parere on 17
November 2011
– Comitato Etico of A.O.U. San Luigi Gonzaga, Orbassano (TO): Prot.
18362 on 23 September 2011
– Comitato Etico of I.R.C.C.S Ospedale Maggiore Policlinico, Milano:
Parere on 13 December 2011
– Comitato Etico of I.R.C.C.S. San Matteo, Pavia: Prot. 48199 on 3 March 2012
– Comitato Etico of A.O. San Giovanni Bosco, Torino: Prot. 43718 on 3
August 2011
Written informed consent was mandatory for all able patients. When it could
not be given, a written declaration of information received was collected
from relatives, according to local ethics committee indications. As soon as
patients’ neurological conditions improved, all enrolled patients were duly
informed of the study and their written consent was obtained, both for the
use of previously collected data, and for all prospective treatments and data
collection. Patients or their next of kin could request withdrawal from the
study at any time.
Consent for publication
Besides informed consent to participate, specific permission to use
anonymized data for scientific purposes was collected from all
patients.
Competing interests
All the authors, the Steering Committee members, and the SedaEN investigators
declare they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università
degli Studi di Milano, A.O. San Paolo - Polo Universitario, Via A. Di Rudinì, 8,
20142 Milano, Italy. 2SC Anestesia e Rianimazione, ASST Santi Paolo e Carlo,
Ospedale San Paolo - Polo Universitario, Milano, Italy. 3Dipartimento di
Economia, Management e Metodi Quantitativi, Università degli Studi di
Milano, Milano, Italy. 4Dipartimento Anestesia, Rianimazione ed
Emergenza-Urgenza, Fondazione IRCCS Ca’Granda, Ospedale Maggiore
Policlinico, Milano, Italy. 5Dipartimento di Scienze della Salute, Università
degli Studi di Milano, Milano, Italy. 6UOC Anestesia e Rianimazione, ASST
Monza, Ospedale di Desio, Monza, Italy. 7UO Anestesia e Rianimazione, ASST
Ovest Milanese, Ospedale Nuovo di Legnano (MI), Legnano, Italy.
8Dipartimento di Medicina e Chirurgia, Università degli Studi Milano Bicocca,
A.O. San Gerardo, Monza, Italy. 9Dipartimento Medicina Intensiva, IRCCS
Fondazione Policlinico San Matteo, Pavia, Italy. 10UO Anestesia e
Rianimazione 2, IRCCS San Matteo, Pavia, Italy. 11SC Anestesia Rianimazione B
DEA, Ospedale San Giovanni Bosco, Torino, Italy. 12SCDU Anestesia e
Rianimazione, AOU San Luigi Gonzaga di Orbassano (TO), Torino, Italy. 13UO
Anestesia e Rianimazione, AO Cardinal Massaia, Asti, Italy. 14UO Anestesia e
Rianimazione, AO Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Mistraletti et al. Critical Care            (2019) 23:3 Page 9 of 10
15UO Anestesia e Rianimazione, Nuovo Ospedale Civile Sant’Agostino
Estense, Modena, Italy.
Received: 16 August 2018 Accepted: 27 November 2018
References
1. Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, Davidson JE, Devlin
JW, Kress JP, Joffe AM, et al. Clinical practice guidelines for the
management of pain, agitation, and delirium in adult patients in the
intensive care unit. Crit Care Med. 2013;41(1):263–306.
2. Nseir S, Makris D, Mathieu D, Durocher A, Marquette CH. Intensive care unit-
acquired infection as a side effect of sedation. Crit Care. 2010;14(2):R30.
3. Vasilevskis EE, Ely EW, Speroff T, Pun BT, Boehm L, Dittus RS. Reducing
iatrogenic risks: ICU-acquired delirium and weakness–crossing the quality
chasm. Chest. 2010;138(5):1224–33.
4. Baron R, Binder A, Biniek R, Braune S, Buerkle H, Dall P, Demirakca S, Eckardt
R, Eggers V, Eichler I, et al. Evidence and consensus based guideline for the
management of delirium, analgesia, and sedation in intensive care
medicine. Revision 2015 (DAS-Guideline 2015) - short version. Ger Med Sci.
2015;13:Doc19.
5. Celis-Rodriguez E, Birchenall C, de la Cal MA, Castorena Arellano G,
Hernandez A, Ceraso D, Diaz Cortes JC, Duenas Castell C, Jimenez EJ, Meza
JC, et al. Clinical practice guidelines for evidence-based management of
sedoanalgesia in critically ill adult patients. Med Int. 2013;37(8):519–74.
6. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, McArthur C,
Seppelt IM, Webb S, Weisbrodt L. Early intensive care sedation predicts
long-term mortality in ventilated critically ill patients. Am J Respir Crit Care
Med. 2012;186(8):724–31.
7. Balzer F, Weiss B, Kumpf O, Treskatsch S, Spies C, Wernecke KD, Krannich A,
Kastrup M. Early deep sedation is associated with decreased in-hospital and
two-year follow-up survival. Crit Care. 2015;19:197.
8. Shah FA, Girard TD, Yende S. Limiting sedation for patients with acute
respiratory distress syndrome - time to wake up. Curr Opin Crit Care. 2017;
23(1):45–51.
9. Oddo M, Crippa IA, Mehta S, Menon D, Payen JF, Taccone FS, Citerio G.
Optimizing sedation in patients with acute brain injury. Crit Care. 2016;
20(1):128.
10. Martin J, Franck M, Fischer M, Spies C. Sedation and analgesia in German
intensive care units: how is it done in reality? Results of a patient-based
survey of analgesia and sedation. Intensive Care Med. 2006;32(8):1137–42.
11. Vincent JL. Give your patient a fast hug (at least) once a day. Crit Care Med.
2005;33(6):1225–9.
12. Cigada M, Corbella D, Mistraletti G, Forster CR, Tommasino C, Morabito A,
Iapichino G. Conscious sedation in the critically ill ventilated patient. J Crit
Care. 2008;23(3):349–53.
13. Vincent JL, Shehabi Y, Walsh TS, Pandharipande PP, Ball JA, Spronk P,
Longrois D, Strom T, Conti G, Funk GC, et al. Comfort and patient-centred
care without excessive sedation: the eCASH concept. Intensive Care Med.
2016;42(6):962–71.
14. Walsh TS, Kydonaki K, Antonelli J, Stephen J, Lee RJ, Everingham K, Hanley J,
Phillips EC, Uutela K, Peltola P, et al. Staff education, regular sedation and
analgesia quality feedback, and a sedation monitoring technology for
improving sedation and analgesia quality for critically ill, mechanically
ventilated patients: a cluster randomised trial. Lancet Respir Med. 2016;
4(10):807–17.
15. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT,
Taichman DB, Dunn JG, Pohlman AS, Kinniry PA, et al. Efficacy and safety of
a paired sedation and ventilator weaning protocol for mechanically
ventilated patients in intensive care (Awakening and Breathing Controlled
trial): a randomised controlled trial. Lancet. 2008;371(9607):126–34.
16. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro
EP, Elswick RK. The Richmond Agitation-Sedation Scale: validity and
reliability in adult intensive care unit patients. Am J Respir Crit Care Med.
2002;166(10):1338–44.
17. Tanaka LM, Azevedo LC, Park M, Schettino G, Nassar AP, Rea-Neto A,
Tannous L, de Souza-Dantas VC, Torelly A, Lisboa T, et al. Early sedation and
clinical outcomes of mechanically ventilated patients: a prospective
multicenter cohort study. Crit Care. 2014;18(4):R156.
18. Devlin JW. The pharmacology of oversedation in mechanically ventilated
adults. Curr Opin Crit Care. 2008;14(4):403–7.
19. Svenningsen H, Egerod I, Videbech P, Christensen D, Frydenberg M,
Tonnesen EK. Fluctuations in sedation levels may contribute to delirium in
ICU patients. Acta Anaesthesiol Scand. 2013;57(3):288–93.
20. Porhomayon J, El-Solh AA, Adlparvar G, Jaoude P, Nader ND. Impact of
sedation on cognitive function in mechanically ventilated patients. Lung.
2016;194(1):43–52.
21. Wanzuita R, Poli-de-Figueiredo LF, Pfuetzenreiter F, Cavalcanti AB, Westphal
GA. Replacement of fentanyl infusion by enteral methadone decreases the
weaning time from mechanical ventilation: a randomized controlled trial.
Crit Care. 2012;16(2):R49.
22. Umbrello M, Mistraletti G, Corbella D, Cigada M, Salini S, Morabito A,
Iapichino G. Bias reduction in repeated-measures observational studies by
the use of propensity score: the case of enteral sedation for critically ill
patients. J Crit Care. 2012;27(6):662–72.
23. Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P,
Ruscica M, Dozio E, Esposti R, DeMartini G, et al. Pharmacokinetics of
orally administered melatonin in critically ill patients. J Pineal Res.
2010;48(2):142–7.
24. Mistraletti G, Mantovani ES, Cadringher P, Cerri B, Corbella D, Umbrello M,
Anania S, Andrighi E, Barello S, Di Carlo A, et al. Enteral vs. intravenous ICU
sedation management: study protocol for a randomized controlled trial.
Trials. 2013;14:92.
25. Mistraletti G, Umbrello M, Sabbatini G, Miori S, Taverna M, Cerri B, Mantovani
ES, Formenti P, Spanu P, D'Agostino A, et al. Melatonin reduces the need for
sedation in ICU patients: a randomized controlled trial. Minerva Anestesiol.
2015;81(12):1298–310.
26. Bourne RS, Mills GH. Melatonin: possible implications for the postoperative
and critically ill patient. Intensive Care Med. 2006;32(3):371–9.
27. Bellapart J, Boots R. Potential use of melatonin in sleep and delirium in the
critically ill. Br J Anaesth. 2012;108(4):572–80.
28. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology
Score (SAPS II) based on a European/North American multicenter study.
JAMA. 1993;270(24):2957–63.
29. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff
T, Gautam S, Margolin R, et al. Delirium in mechanically ventilated patients:
validity and reliability of the confusion assessment method for the intensive
care unit (CAM-ICU). JAMA. 2001;286(21):2703–10.
30. Awissi DK, Begin C, Moisan J, Lachaine J, Skrobik Y. I-SAVE study: impact of
sedation, analgesia, and delirium protocols evaluated in the intensive care
unit: an economic evaluation. Ann Pharmacother. 2012;46(1):21–8.
31. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill
patients receiving mechanical ventilation: a randomised trial. Lancet. 2010;
375(9713):475–80.
32. Maccioli GA, Dorman T, Brown BR, Mazuski JE, McLean BA, Kuszaj JM,
Rosenbaum SH, Frankel LR, Devlin JW, Govert JA, et al. Clinical practice
guidelines for the maintenance of patient physical safety in the intensive
care unit: use of restraining therapies--American College of Critical Care
Medicine Task Force 2001-2002. Crit Care Med. 2003;31(11):2665–76.
33. Stroem T, Toft P. Optimizing sedation in critically ill patients: by technology
or change of culture? J Thorac Dis. 2016;8(12):E1676–8.
34. Mistraletti G, Umbrello M, Anania S, Andrighi E, DI Carlo A, Martinetti F,
Barello S, Sabbatini G, Formenti P, Maraffi T, et al. Neurological assessment
with validated tools in general ICU: multicenter, randomized, before
and after, pragmatic study to evaluate the effectiveness of an e-learning
platform for continuous medical education. Minerva Anestesiol. 2017;
83(2):145–54.
35. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gogenur I. Analgesic effects
of melatonin: a review of current evidence from experimental and clinical
studies. J Pineal Res. 2011;51(3):270–7.
36. Toft P, Olsen HT, Jorgensen HK, Strom T, Nibro HL, Oxlund J, Wian KA,
Ytrebo LM, Kroken BA, Chew M. Non-sedation versus sedation with a
daily wake-up trial in critically ill patients receiving mechanical ventilation
(NONSEDA Trial): study protocol for a randomised controlled trial. Trials.
2014;15:499.
Mistraletti et al. Critical Care            (2019) 23:3 Page 10 of 10
